Evidence-based recommendations on the treatment of von Willebrand disease in Italy

Pier O. Mannucci, Massimo Franchini, Giancarlo Castaman, Augusto B. Federici

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background. von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII). Material and methods. This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease. Results and conclusions. Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.

Original languageEnglish
Pages (from-to)117-126
Number of pages10
JournalBlood Transfusion
Volume7
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

von Willebrand Diseases
Deamino Arginine Vasopressin
Type 1 von Willebrand Disease
Italy
Factor VIII
von Willebrand Factor
Type 3 Von Willebrand's Disease
Type 2 von Willebrand Disease
Hemorrhage
Hemophilia A
Hemostasis
Meta-Analysis
Mucous Membrane
Therapeutics
Randomized Controlled Trials
Membranes
factor VIII, von Willebrand factor drug combination

Keywords

  • Desmopressin
  • Von Willebrand disease
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Evidence-based recommendations on the treatment of von Willebrand disease in Italy. / Mannucci, Pier O.; Franchini, Massimo; Castaman, Giancarlo; Federici, Augusto B.

In: Blood Transfusion, Vol. 7, No. 2, 2009, p. 117-126.

Research output: Contribution to journalArticle

Mannucci, Pier O. ; Franchini, Massimo ; Castaman, Giancarlo ; Federici, Augusto B. / Evidence-based recommendations on the treatment of von Willebrand disease in Italy. In: Blood Transfusion. 2009 ; Vol. 7, No. 2. pp. 117-126.
@article{e8649f030a474ef292e0bc9f71174a02,
title = "Evidence-based recommendations on the treatment of von Willebrand disease in Italy",
abstract = "Background. von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII). Material and methods. This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease. Results and conclusions. Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.",
keywords = "Desmopressin, Von Willebrand disease, Von Willebrand factor",
author = "Mannucci, {Pier O.} and Massimo Franchini and Giancarlo Castaman and Federici, {Augusto B.}",
year = "2009",
doi = "10.2450/2008.0052-08",
language = "English",
volume = "7",
pages = "117--126",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "2",

}

TY - JOUR

T1 - Evidence-based recommendations on the treatment of von Willebrand disease in Italy

AU - Mannucci, Pier O.

AU - Franchini, Massimo

AU - Castaman, Giancarlo

AU - Federici, Augusto B.

PY - 2009

Y1 - 2009

N2 - Background. von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII). Material and methods. This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease. Results and conclusions. Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.

AB - Background. von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII). Material and methods. This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease. Results and conclusions. Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.

KW - Desmopressin

KW - Von Willebrand disease

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=66349136610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349136610&partnerID=8YFLogxK

U2 - 10.2450/2008.0052-08

DO - 10.2450/2008.0052-08

M3 - Article

C2 - 19503633

AN - SCOPUS:66349136610

VL - 7

SP - 117

EP - 126

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 2

ER -